Novo Nordisk sues Viatris over copycat Wegovy
A market authorization application from US-based generics maker Viatris for a copy version of obesity treatment Wegovy breaches five of Novo Nordisk’s patents, claims the company in a lawsuit.
by christian bundgaard, translated by daniel pedersen
Viatris, a US-based producer of generic medicines, is training its sights on Novo Nordisk’s golden goose, obesity treatment Wegovy, and has filed for market clearance for a copycat version in the US.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk doubles obesity sales in 2022
For subscribers
.jpg&w=384&q=75)
